Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A. is dated May 19, 2025. The report serves as a vehicle to disseminate a press release (Exhibit 99.1) issued on the same date. The registrant is a foreign private issuer based in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The filing text provided does not contain specific financial data. There are no disclosed values for revenue, profit, cash flow, margins, debt, or liquidity in this document. The filing consists solely of the cover page and an exhibit index referencing an external press release.
Material Changes
No material changes versus prior periods are detailed in the provided text. The document does not include comparative financial statements or operational updates.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These elements are likely contained within the referenced press release (Exhibit 99.1), which is not included in the input content.
Key Facts for Investor Verification
- The filing is a procedural Form 6-K referencing a press release dated May 19, 2025.
- No financial figures or operational metrics are present in the provided text.
- Investors must review the full text of Exhibit 99.1 (the press release) to obtain the substance of the announcement.
- The report is signed by Jonathan Dickinson, Chairman of the Executive Board and CEO.